

R H I N O M E D

Results of the RNO Off-Market Minimum Holding Share Buy-Back

2 February 2024: Melbourne, Australia.

Rhinomed Limited (ASX: RNO, OTCQB:RHNMF) (**RNO** or the **Company**) announced to the ASX on 11 December 2023 a minimum holding share buy-back offer (**Unmarketable Parcels Buy-Back**) to RNO shareholders who held less than a marketable parcel of RNO shares as at the Record Date of 8 December 2023 (**Eligible Shareholders**).

RNO provided the Unmarketable Parcels Buy-Back offer to Eligible Shareholders to facilitate the sale of their shares without any brokerage fee or handling costs, at a price of \$0.04 per share which was the volume weighted average price of RNO shares on ASX for the 5 trading days ending on the Record Date (rounded to the nearest half cent). Eligible Shareholders were defined as any shareholder with a total holding of 12,500 shares or less. This allowed 789 Eligible Shareholders to participate in the Unmarketable Parcels Buy-Back. Eligible Shareholders had until 7.00pm (AEDT) on Wednesday, 31 January 2024 to opt-out of the Unmarketable Parcels Buy-Back or increase their shareholding to a marketable parcel.

The total number of ordinary shares to be bought back under the Unmarketable Parcel Buy-Back has provisionally been determined as 3,250,644 shares, held by 690 Eligible Shareholders. This represents approximately 1% of RNO's share capital.

Payment of the purchase money for shares bought back in the Unmarketable Parcels Buy-Back will be made by RNO in the coming days, by remittance to each individual selling Eligible Shareholder's bank account as registered with RNO's share registry, Automic, or by cheque if no bank account is registered with Automic.

This announcement has been authorised for release to the market by the Company Secretary.

Company	Investor and Media Relations
Michael Johnson, CEO & Director +61 (0) 3 8416 0900 mjohnson@rhinomed.global Follow us on Twitter @rhinomedceo	Rudi Michelson Monsoon Communications +61(0) 411 402 737 rudim@monsoon.com.au

About Rhinomed Limited (ASX: RNO, OTCQB:RHNMF)

Rhinomed Limited is a Melbourne, Australia based ASX listed nasal and airway technology company that has developed an innovative nasal technology platform that can improve air flow and provide both drug delivery and diagnostic capabilities.